OzlemGoker-AlpanMD

Medical Genetics • Fairfax, VA

Clinical Genetics

Physician

Join to view full profile

Dr. Goker-Alpan is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Goker-Alpan's full profile

Already have an account?

Office
3702 Pender Drive
Ste 170
Fairfax, VA 22030
Phone+1 703-261-6220

Education & Training

National Institutes of Health Clinical CenterResidency, Medical Genetics and Genomics, 1996 - 1999
Stony Brook Medicine/University HospitalResidency, Pediatrics, 1992 - 1996
Marmara Univ- Fac MedClass of 1990

Clinical Trials

Safety and Efficacy Study of Several Replagal Dosing Regimens on Cardiac Function in Adults With Fabry Disease Start of enrollment: 2008 Dec 29
Completed
Phase 3
Treatment Protocol of Replagal for Patients With Fabry Disease
No longer available
Exploration of Immunity in Gaucher Disease Start of enrollment: 2011 Apr 01
Completed
Pregnancy and Birth Outcome in Women With Pompe Disease Start of enrollment: 2012 Feb 01
Completed
Molecular and Cellular Mechanisms of Lysosomal Storage Diseases Start of enrollment: 2013 Nov 01
Recruiting
Open-Label Extension Study of the Long-Term Effects of Migalastat HCL in Patients With Fabry Disease Start of enrollment: 2015 Mar 14
Completed
Phase 3
First-In-Human Study to Evaluate Safety, Tolerability, and PK of Intravenous ATB200 Alone and When Co-Administered With Oral AT2221
COMPLETED
PHASE1, PHASE2
Biomarker Analysis for GBA Associated Parkinson's Disease Start of enrollment: 2018 Feb 01
Recruiting
Screening of Lysosomal Storage Disorders Diseases in Minority Groups Start of enrollment: 2016 Mar 17
Active, not recruiting
Cellular Pharmacodynamics of Small Molecules in Lysosomal Storage Disorders Start of enrollment: 2018 Jul 06
Recruiting
Immune Biomarkers Related to Bone Pathology in Patients With Type 1 Gaucher Disease Start of enrollment: 2019 May 15
Recruiting
Assess Urine Biomarkers to Predict Nephropathy in Fabry Disease Start of enrollment: 2023 Sep 14
Recruiting
Roles: Principal Investigator, Contact
Join now to see all

Publications & Presentations

PubMed

Sex Differences in Circulating Inflammatory, Immune, and Tissue Growth Markers Associated with Fabry Disease-Related Cardiomyopathy.
Margarita M Ivanova, Julia Dao, Andrew Friedman, Neil Kasaci, Ozlem Goker-Alpan
Cells. 2025-02-20
Correction: Long-term safety and efficacy of cipaglucosidase alfa plus miglustat in individuals living with Pompe disease: an open-label phase I/II study (ATB200-02).
Barry J Byrne, Benedikt Schoser, Priya S Kishnani, Drago Bratkovic, Paula R Clemens
Journal of Neurology. 2025-02-17
3 citations
A phase III, open-label clinical trial evaluating pegunigalsidase alfa administered every 4 weeks in adults with Fabry disease previously treated with other enzyme rep...
Myrl Holida, Aleš Linhart, Antonio Pisani, Nicola Longo, François Eyskens
Journal of Inherited Metabolic Disease. 2025-01-01